In yet another move to pay down debt that matures in 2026, Walgreens Boots Alliance announced last night it would receive $300 million from an early settlement of some prepaid shares of Cencora along ...

Cencora assumes no obligation to update any ... in specialty in a high growth pharmaceutical-centric segment, building on our services for our customers and positioning us well in a medical ...

Over the past year, many Cencora, Inc. ( NYSE:COR ) insiders sold a significant stake in the company which may have... CONSHOHOCKEN, Pa., February 07, 2025--Cencora, Inc. (NYSE: COR) today ...

Cencora assumes no obligation to update any ... leadership in specialty in a high-growth pharmaceutical-centric segment building on our services for our customers and positioning us well in ...

Cencora posted Q1 sales of $81.5 billion, exceeding forecasts, with strong GLP-1 drug sales. Adjusted EPS beat estimates, and FY25 guidance was raised.

For the quarter ended December 2024, Cencora (COR) reported revenue of $81.49 billion, up 12.8% over the same period last year. EPS came in at $3.73, compared to $3.28 in the year-ago quarter.

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal first-quarter net income of $488.6 million. The Conshohocken, Pennsylvania-based company said ...

Cencora (COR) came out with quarterly earnings of $3.73 per share, beating the Zacks Consensus Estimate of $3.50 per share. This compares to earnings of $3.28 per share a year ago. These figures ...